Complete Up To Date Information about Parvex Suspension.
NADA Number: 011-299 | |
| Proprietary Name |
Parvex® Suspension |
|---|---|
| Sponsor |
Pharmacia & Upjohn Co. |
| Sponsor Address |
a Division of Pfizer, Inc. 235 East 42nd St. New York, NY 10017 USA |
| Ingredients |
Piperazine-carbon Disulfide Complex |
| Species |
Horse, no use class stated or implied Pony, no use class stated or implied |
| Routes of Administration |
Nasogastic intubation |
| Dose Form |
Liquid (suspension) |
| Drug Form |
Liquid (suspension) |
| Dispensing Status |
RX |
|
Dosage Amount, Indications & Limitations |
520.1802a Piperazine-carbon disulfide complex suspension. Specifications: Each fluid ounce of suspension contains 7.5 grams of piperazine-carbon disulfide complex. The piperazine-carbon disulfide complex contains equimolar parts of piperazine and carbon disulfide (1 gram contains 530 milligrams of piperazine and 470 milligrams of carbon disulfide). Conditions of use: Horses (and ponies) Amount: One fluid ounce per 100 pounds of body weight. Indications: For removing ascarids (large roundworms, Parascaris equorum), bots (Gastrophilus species), small strongyles, large strongyles (Strongyles species), and pinworms (Oxyuris equi). Limitations: Administer by stomach tube or dose syringe after withholding feed overnight or for 8 to 10 hours. Provide water as usual. Resume regular feeding 4 to 6 hours after treatment. Treatment of debilitated or anemic animals is contraindicated. Do not administer to animals that are or were recently affected with colic, diarrhea, or infected with a serious infectious disease. As with most anthelmintics drastic cathartics and other gastrointestinal irritants should not be administered in conjunction with this drug. Animals in poor condition or heavily parasitized should be given one half the recommended dose and treated again in 2 or 3 weeks. Federal law restricts this drug to use by or on the order of a licensed veterinarian. NAS/NRC status: These conditions are NAS/NRC reviewed and found effective. Applications for these uses need not include effectiveness data as specified by 514.111 of this chapter, but may require bioequivalency and safety information. |